News: CSL UPDATE 1-Biotech firm CSL's full-year profit rises on higher plasma collections, page-53

Not a great fan of Motley Fool but this is their current summary of broker sentiment.

"Should you buy?
Let’s canvas the views of the experts.

Macquarie retained its outperform rating and $326 share price target after CSL reported its results.

Morgans has held firm with its add rating and an improved share price target of $328.20.

UBS stuck with its buy rating and $340 price target.

Citi maintains its a buy rating on CSL shares with a reduced price target from $340 to $325.

Goldman Sachs maintains a neutral rating and has a $296 price target. It describes CSL as “oversold”.

Goldman says:

We continue to believe the shares look oversold (market-relative P/E has de-rated from 2.7x to 1.7x in the last 10 months, and our TP of $296 implies +9% upside from today’s close)."